Cardiol Therapeutics (CRDL) to present CardiolRx™ pipeline at B. Riley Mind, Muscle & Vision Summit

Rhea-AI Filing Summary

Cardiol Therapeutics Inc. reported that it will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston on July 16, 2026, at 12:20 p.m. Eastern Time. This is an investor-focused conference appearance, not a financial results update.

The company highlights its late-stage development of CardiolRx™, a small-molecule drug targeting inflammasome pathway activation for heart conditions including recurrent pericarditis and acute myocarditis, and its pivotal Phase III MAVERIC trial. Cardiol is also developing CRD-38, a subcutaneous therapy candidate for inflammatory heart disease, including heart failure.

Key Figures

Summit presentation time: July 16, 2026 at 12:20 p.m. Eastern Time Heart failure healthcare costs: US$30 billion per year Orphan Drug Designation: Granted for pericarditis, including recurrent pericarditis

3 metrics

Summit presentation time July 16, 2026 at 12:20 p.m. Eastern Time B. Riley Securities Mind, Muscle & Vision Summit fireside chat

Heart failure healthcare costs US$30 billion per year Estimated annual heart failure-related healthcare costs in the United States

Orphan Drug Designation Granted for pericarditis, including recurrent pericarditis U.S. FDA status for CardiolRx™

Key Terms

Orphan Drug Designation, Phase III MAVERIC trial, recurrent pericarditis, acute myocarditis, +1 more

5 terms

Orphan Drug Designation regulatory

"The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

Phase III MAVERIC trial financial

"the ongoing pivotal Phase III MAVERIC trial (NCT06708299)"

recurrent pericarditis medical

"The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis"

Inflammation of the thin sac around the heart that comes back after a first episode. Like a door that keeps sticking shut even after being fixed, recurrent pericarditis involves repeated bouts of chest pain, fever, or fatigue that can require ongoing treatment, tests, or even procedures. Investors track it because recurrent disease affects healthcare spending, drug trial design, regulatory review, and the potential market for therapies aimed at preventing or managing flare-ups.

acute myocarditis medical

"The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis"

Acute myocarditis is a sudden inflammation of the heart muscle that can weaken the heart’s ability to pump and cause irregular rhythms, often requiring medical treatment or hospitalization. For investors, it matters because cases can affect employee or executive health, trigger product safety or clinical-trial concerns, increase medical and legal costs, and prompt regulatory scrutiny—similar to how a jammed pump can slow down an entire factory’s output and raise repair bills.

forward-looking information regulatory

"This news release contains "forward-looking information" within the meaning of applicable securities laws."

Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/09/2026 - 07:53 AM Accepted by SEC EDGAR 07/09/2026 - 07:52 AM Learn about SEC filing dates

FAQ

What did Cardiol Therapeutics (CRDL) announce in this 6-K filing?

Cardiol Therapeutics announced it will participate in a fireside chat at the B. Riley Securities Mind, Muscle & Vision Summit. The company also reiterated its focus on CardiolRx™ and CRD-38, late-stage therapies targeting inflammatory heart diseases including recurrent pericarditis and heart failure.

When and where will Cardiol Therapeutics present at the B. Riley Summit?

Cardiol Therapeutics will participate in a fireside chat on July 16, 2026, at 12:20 p.m. Eastern Time. The event takes place at the InterContinental Boston Hotel, specifically in the Abigail Adams Salon B, as part of B. Riley Securities’ Mind, Muscle & Vision Summit.

What is Cardiol Therapeutics’ lead drug candidate CardiolRx™?

CardiolRx™ is Cardiol Therapeutics’ lead small-molecule drug candidate aimed at modulating inflammasome pathway activation. It is being developed for inflammatory heart conditions such as recurrent pericarditis and acute myocarditis, which can cause chest pain, shortness of breath, fatigue, and serious cardiac complications.

Which clinical programs for CardiolRx™ are highlighted by Cardiol Therapeutics (CRDL)?

Cardiol highlights the MAVERIC Program in recurrent pericarditis, including a completed Phase II MAvERIC-Pilot study and an ongoing pivotal Phase III MAVERIC trial. The company also references the ARCHER Program, a completed Phase II study evaluating CardiolRx™ in patients with acute myocarditis and associated heart failure.

What regulatory status has CardiolRx™ received for treating pericarditis?

The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis. This designation is intended for therapies targeting rare conditions and can provide certain regulatory and economic incentives during development and potential commercialization.

What is CRD-38 and what condition is Cardiol Therapeutics targeting?

CRD-38 is a novel, subcutaneously administered drug formulation being developed by Cardiol Therapeutics. It is intended for treating inflammatory heart disease, including heart failure, a leading cause of death and hospitalization in developed countries and a major driver of healthcare costs in the United States.

How large is the economic burden of heart failure mentioned by Cardiol Therapeutics?

Cardiol Therapeutics notes that heart failure is associated with healthcare costs in the United States exceeding US$30 billion per year. This figure underscores the significant economic impact of heart failure and the potential importance of new therapies targeting inflammatory mechanisms in this condition.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated July 9, 2026 - Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: July 9, 2026	By:	/s/ Christopher Waddick
		Christopher Waddick
	Title:	Chief Financial Officer

EXHIBIT 99.1

Cardiol Therapeutics to Participate in Fireside Chat at B. Riley Securities Mind, Muscle & Vision Summit

TORONTO, July 9, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that it will participate in a Fireside Chat at the B. Riley Securities Mind, Muscle & Vision Summit in Boston, MA, on July 16, 2026, at 12:20 p.m. EDT.

B. Riley Securities Mind, Muscle & Vision Summit
When: Thursday, July 16 at 12:20 p.m. Eastern Time.
Where: InterContinental Boston Hotel, in Abigail Adams Salon B

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program also studied CardiolRx™, specifically in acute myocarditis--an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure--a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission (as part of its Annual Report on Form 40-F) on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiol-therapeutics-to-participate-in-fireside-chat-at-b-riley-securities-mind-muscle--vision-summit-302821386.html

SOURCE Cardiol Therapeutics Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2026/09/c7422.html

%CIK: 0001702123

For further information: For further information, please contact: Investor.relations@cardiolrx.com

CO: Cardiol Therapeutics Inc.

CNW 07:27e 09-JUL-26

Filing Exhibits & Attachments

1 document

Press Releases

• EX-991 NEWS RELEASE DATED JULY 9, 2026 8.2 KB